We updated the Mycophenolic acid Pathway in collaboration with Kinjal Sanghavi and Dr. Vishal Lamba from the University of Minnesota.
Mycophenolic Acid (MPA) is an immunosuppressive agent and is indicated as prophylactic agent in patients receiving allogeneic renal, cardiac or hepatic transplants.
This PharmGKB pathway describes the steps and metabolites involved in the pharmacokinetic of mycophenolate mofetil, the prodrug of MPA.
The target of MPA is the inosine monophosphate dehydrogenase, which is an important rate limiting enzyme involved in purine synthesis. The pharmacodynamic section highlights several mechanisms of action of MPA.
Genetic variants within genes involved in MPA uptake and metabolism, and in its targets have been reported to affect MPA response in patients undergoing transplantation. For more information read the entire pathway description of the Mycophenolic acid Pathway at PharmGKB.
View all pathways at PharmGKB.